FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892263805> ?p ?o ?g. }

• W2892263805 abstract "TPS8584 Background: The first-line standard of care for the majority of patients (pts) with extensive-stage small-cell lung cancer (ES-SCLC) is platinum-based chemotherapy with etoposide, but survival outcomes remain poor (median OS, < 1 year) despite initial response rates ranging from 50-70%. Atezolizumab (atezo), an anti–PD-L1 mAb, prevents the binding of PD-L1 with its receptors PD-1 and B7.1 and restores anticancer T-cell activity. Tolerable safety with promising durability of response has been shown with atezo in pts with ES-SCLC: confirmed ORR was 6% (n = 1/17 [partial response]; DOR of 7 mo) by RECIST v1.1 and 24% by immune-related response criteria (irRC; n = 4/17, with 2 pts on atezo for ≥ 12 mo). Preliminary data also indicate the potential synergy between atezo and platinum-based chemotherapy in NSCLC, whereby durable responses may translate into improved survival over atezo alone. IMpower133 (NCT02763579), a global, Phase I/III, randomized, multicenter, double-blinded, placebo-controlled trial will evaluate the efficacy and safety of 1L atezo + carboplatin + etoposide compared with placebo + carboplatin + etoposide in treatment-naive pts with ES-SCLC. Methods: Pts with measurable (RECIST v1.1) ES-SCLC, who have ECOG PS 0-1 and no prior systemic anticancer treatment, are eligible for the study. Exclusion criteria include untreated CNS metastases and history of autoimmune disease. The study requires submission of tumor tissue, but pts will be enrolled regardless of biomarker status. Pts will be stratified by sex, ECOG PS and presence of treated brain metastases. Eligible pts will be randomized 1:1 to receive four 21-day cycles of atezo (1200 mg IV) or placebo in combination with carboplatin (AUC 5 mg/mL/min IV, d 1) and etoposide (100 mg/m 2 IV, d 1-3), followed by maintenance therapy with atezo or placebo until PD per RECIST v1.1. Pts can continue with treatment until persistent radiographic PD, symptomatic deterioration or unacceptable toxicity. Co-primary endpoints are investigator-assessed PFS per RECIST v1.1 and OS. Secondary efficacy endpoints include investigator-assessed ORR and DOR. Safety and tolerability will also be assessed. Approximately 400 pts will be enrolled. Clinical trial information: NCT02763579." @default.
• W2892263805 created "2018-09-27" @default.
• W2892263805 creator A5006496749 @default.
• W2892263805 creator A5019770739 @default.
• W2892263805 creator A5041853768 @default.
• W2892263805 creator A5043871151 @default.
• W2892263805 creator A5044613951 @default.
• W2892263805 creator A5060572768 @default.
• W2892263805 creator A5062012068 @default.
• W2892263805 creator A5062894702 @default.
• W2892263805 creator A5066717752 @default.
• W2892263805 creator A5071440718 @default.
• W2892263805 creator A5072962574 @default.
• W2892263805 date "2017-05-20" @default.
• W2892263805 modified "2023-09-26" @default.
• W2892263805 title "Phase I/III trial of atezolizumab with carboplatin and etoposide in ES-SCLC in first-line setting (IMpower133)." @default.
• W2892263805 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.tps8584" @default.
• W2892263805 hasPublicationYear "2017" @default.
• W2892263805 type Work @default.
• W2892263805 sameAs 2892263805 @default.
• W2892263805 citedByCount "2" @default.
• W2892263805 countsByYear W28922638052019 @default.
• W2892263805 countsByYear W28922638052022 @default.
• W2892263805 crossrefType "journal-article" @default.
• W2892263805 hasAuthorship W2892263805A5006496749 @default.
• W2892263805 hasAuthorship W2892263805A5019770739 @default.
• W2892263805 hasAuthorship W2892263805A5041853768 @default.
• W2892263805 hasAuthorship W2892263805A5043871151 @default.
• W2892263805 hasAuthorship W2892263805A5044613951 @default.
• W2892263805 hasAuthorship W2892263805A5060572768 @default.
• W2892263805 hasAuthorship W2892263805A5062012068 @default.
• W2892263805 hasAuthorship W2892263805A5062894702 @default.
• W2892263805 hasAuthorship W2892263805A5066717752 @default.
• W2892263805 hasAuthorship W2892263805A5071440718 @default.
• W2892263805 hasAuthorship W2892263805A5072962574 @default.
• W2892263805 hasConcept C121608353 @default.
• W2892263805 hasConcept C126322002 @default.
• W2892263805 hasConcept C143998085 @default.
• W2892263805 hasConcept C2775949291 @default.
• W2892263805 hasConcept C2776694085 @default.
• W2892263805 hasConcept C2777701055 @default.
• W2892263805 hasConcept C2778119113 @default.
• W2892263805 hasConcept C2778239845 @default.
• W2892263805 hasConcept C2780057760 @default.
• W2892263805 hasConcept C2781451048 @default.
• W2892263805 hasConcept C71924100 @default.
• W2892263805 hasConceptScore W2892263805C121608353 @default.
• W2892263805 hasConceptScore W2892263805C126322002 @default.
• W2892263805 hasConceptScore W2892263805C143998085 @default.
• W2892263805 hasConceptScore W2892263805C2775949291 @default.
• W2892263805 hasConceptScore W2892263805C2776694085 @default.
• W2892263805 hasConceptScore W2892263805C2777701055 @default.
• W2892263805 hasConceptScore W2892263805C2778119113 @default.
• W2892263805 hasConceptScore W2892263805C2778239845 @default.
• W2892263805 hasConceptScore W2892263805C2780057760 @default.
• W2892263805 hasConceptScore W2892263805C2781451048 @default.
• W2892263805 hasConceptScore W2892263805C71924100 @default.
• W2892263805 hasLocation W28922638051 @default.
• W2892263805 hasOpenAccess W2892263805 @default.
• W2892263805 hasPrimaryLocation W28922638051 @default.
• W2892263805 isParatext "false" @default.
• W2892263805 isRetracted "false" @default.
• W2892263805 magId "2892263805" @default.
• W2892263805 workType "article" @default.